EN DE
Watch Organoclick AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Organoclick AB (ORGC) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Organoclick AB stock SEK 0.36, price SEK 0.42, that is 14.4% below the price, quality 17 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials SE · ISIN SE0006510335

OA Organoclick AB logo Thin data Nov 10, 2026

Organoclick AB

ORGC · ST
Expensive, weak quality

Our calculation puts a fair price 14% below what the stock costs today.

Low debt
Revenue last quarter 26% below a year ago.
Fair value kr 0.3594 · Overvalued
Quality 17/100
Weak Growth (revenue 5y +1.9 %/yr in SEK)
Loss-making · -35.7% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 11/100 · thin data
Thin data
⟳ CyclicalEstimate
Watch Organoclick AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 12.34 kr 0.2050 Fair Value kr 0.3594 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.2050 – kr 12.34 · fair‑value band kr 0.2695 – kr 0.4492 · the kr 0.4200 price screens above the kr 0.3594 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow Organoclick in your weekly email

Every Wednesday you see whether Organoclick is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

OrganoClick AB (publ), a green chemical company, develops and markets biobased and biodegradable chemical products and material technologies for the treatment of nonwoven, technical textile, and wood in Sweden, Other Nordics, the Rest of Europe, Asia, North America, and Oceania.

Show moreShow less

The company offers OrganoTex, a biodegradable and durable water repellent (DWR) technology for textile and shoe impregnation, and detergents; OrganoWood, a timber product and a wood preservative technology that provides wood with protection against decay and termites; and OrganoComp, a bio composite that is used for 3D forming.

It also provides BIOkleen maintenance and cleaning products, as well as paint removal products; OC-BioBinder, a biobased and biodegradable binder used in nonwoven and technical textiles; and OC-AquaSil Tex, a biodegradable hydrophobing product used in nonwovens, specialty papers, and technical textiles.

The company sells its products through a network of retailers. It serves the nonwoven, paper, textile, wood treatment, and construction industries, as well as consumers and homeowners. OrganoClick AB (publ) was incorporated in 2006 and is headquartered in Täby, Sweden.

Stock analysis

Organoclick AB (ORGC) currently trades at kr 0.4200, while our estimate is kr 0.3594, 14% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.2695 (bear) to kr 0.4492 (bull), the price of kr 0.4200 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 17/100 (below-average quality), in the Basic Materials sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Organoclick AB reported revenue of 106M SEK in FY2025 versus 110M SEK in FY2021, a compound −0.9%/yr. Reported net income was −36.4M SEK in FY2025.

Key figures

Market cap 89.6M SEK (≈ $9.1M) Micro · P/S ratio 0.99 · EPS (TTM) kr −0.3200 · Net margin −35.7% · Return on equity −156% · Return on assets (EBIT) −15.4% (5-year average) · Operating margin −9.2% · Revenue (TTM) 90.3M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (low confidence).

What moves the price

The share trades about 77% below its 52-week high and 105% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −41% fair-value upside, at −14%, ORGC screens cheaper than that median.

Fair Value

Bear kr 0.2695 Fair Value kr 0.3594 Bull kr 0.4492
Price kr 0.4200 · Downside -14.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 17/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 15
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 2
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 42
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 21
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 9/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−16.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Start year 2020 (pandemic). Over 10 years: +13.3% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−17.9% (2020) → −29.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ORGC screens overvalued: fair value 14% below the price. Compare with Linde plc →

Compare Organoclick AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 758 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 17 · Bottom 25%
Fair Value upside −14.4% · Above median
Profitability
Return on assets −26.9% · Bottom 25%
Net margin (12 months) −35.7% · Bottom 25%
Operating margin (12 months) −9.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −26.3% · Bottom 25%
Balance sheet
Debt / equity 0.23× · Above median

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/B 5.90× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.99× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)14 · sector 4
FUTURE (revenue growth)0 · sector 65
PAST (return on equity)0 · sector 25
HEALTH (low debt)89 · sector 95
DIVIDEND (yield)0 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Nan Ya Plastics Corporation 1303 289.00 TWD 462.40 TWD +60% vs ORGC
Wanhua Chemical Group 600309 ¥71.74 ¥68.03 −5% vs ORGC
Linde plc LIN $521.78 $446.62 −14% vs ORGC
PPG Industries, Inc PPG $124.42 $77.68 −38% vs ORGC
DSM-Firmenich AG DSFIR CHF 97.25 CHF 57.84 −41% vs ORGC
Sika AG SIKA CHF 194.00 CHF 98.89 −49% vs ORGC
The Sherwin-Williams Company SHW $355.34 $146.37 −59% vs ORGC
Givaudan SA GIVN CHF 4,048 CHF 1,554 −62% vs ORGC
Ecolab Inc ECL $306.03 $96.56 −68% vs ORGC
Air Products and Chemicals, Inc APD $312.25 $75.33 −76% vs ORGC

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Organoclick AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Organoclick AB Fair Value". https://www.fairvalue-calculator.com/stock/ORGC

Frequently asked questions

Is Organoclick AB (ORGC) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 0.3594 versus a price of kr 0.4200, about 14% lower (overvalued).
What is the fair value of ORGC?
Our estimate for Organoclick AB is kr 0.3594 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 0.4200.
What is the quality score of ORGC?
Organoclick AB has a Quality Score of 17/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Organoclick AB (ORGC)?
Our calculated price target is the estimate of kr 0.3594 (as of Nov 10, 2026). Cautious scenario kr 0.2695, optimistic scenario kr 0.4492. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Organoclick AB stock forecast for 2026?
Our estimate puts fair value at kr 0.3594, about 14% lower versus a price of kr 0.4200 (overvalued). Cautious scenario kr 0.2695, optimistic scenario kr 0.4492. The calculation is refreshed regularly with new filings.
What is the revenue of Organoclick AB (ORGC)?
Organoclick AB reported trailing-twelve-month revenue of about 90.3M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Organoclick AB (ORGC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Organoclick AB it is kr 0.3594 per share (as of Nov 10, 2026), against a price of kr 0.4200.
Is Organoclick AB stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ORGC trades above its calculated fair value: price kr 0.4200, fair value kr 0.3594, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ORGC?
No. The price is what the market pays today (kr 0.4200); the fair value is what the company's own numbers justify (kr 0.3594). For Organoclick AB the two are kr 0.0606 per share apart. That gap is exactly why we show both numbers side by side.
How much is Organoclick AB worth?
The market values Organoclick AB at about 89.6M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 0.4200; our models calculate a fair value of kr 0.3594 per share.
What do the bullish and bearish scenarios say about ORGC?
Our models span a range for Organoclick AB: cautious scenario kr 0.2695, base kr 0.3594, optimistic kr 0.4492 per share (as of Nov 10, 2026, price kr 0.4200). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Organoclick AB (ORGC)?
Balance-sheet figures for Organoclick AB (as of Nov 10, 2026): return on equity −155.7%, debt of 0.23 per unit of equity. They feed the Quality Score of 17/100, which measures business quality independently of the share price.
How far is ORGC from its 52-week high?
Organoclick AB trades at kr 0.4200, about 77% below its 52-week high of kr 1.81 and 105% above the low of kr 0.2050 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.3594 is for.
Which stocks are comparable to Organoclick AB?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Organoclick AB stock attractive at the current price?
The data as of Nov 10, 2026: price kr 0.4200, calculated fair value kr 0.3594 (−14%), Quality Score 17/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Organoclick AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Organoclick AB (ORGC)?
The closing price on Nov 10, 2026 was kr 0.4200. Our estimate is kr 0.3594, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Organoclick AB right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Organoclick AB

How large is the market capitalisation of Organoclick AB (ORGC)?
The market capitalisation of Organoclick AB is 89.6M SEK (≈ $9.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Organoclick AB (ORGC)?
The price-to-sales ratio of Organoclick AB is 0.99 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Organoclick AB (ORGC)?
Earnings per share at Organoclick AB are kr −0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Organoclick AB (ORGC)?
The net margin of Organoclick AB is −35.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Organoclick AB (ORGC)?
The return on equity (ROE) of Organoclick AB is −156% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Organoclick AB (ORGC)?
On an EBIT basis the return on assets of Organoclick AB is −15.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Organoclick AB (ORGC)?
The operating margin of Organoclick AB is −9.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Organoclick AB (ORGC)?
Revenue at Organoclick AB is growing −26.3% versus a year earlier (3y avg −2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Organoclick AB (ORGC) generate?
The free cash flow of Organoclick AB is −10.5M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Organoclick AB (ORGC) carry?
The net debt of Organoclick AB is 75.1M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Organoclick AB in the live analysis

One click puts Organoclick AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.